Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer

DOI 機関リポジトリ Web Site PubMed 参考文献14件
  • Tanaka Takaaki
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Taoka Masataka
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Makimoto Go
    Department of Respiratory Medicine, Okayama University Hospital, Japan Center for Clinical Oncology, Okayama University Hospital, Japan
  • Ninomiya Kiichiro
    Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan
  • Higo Hisao
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Fujii Masanori
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Ichihara Eiki
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Ohashi Kadoaki
    Department of Respiratory Medicine, Okayama University Hospital, Japan
  • Hotta Katsuyuki
    Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
  • Tabata Masahiro
    Center for Clinical Oncology, Okayama University Hospital, Japan
  • Maeda Yoshinobu
    Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

この論文をさがす

抄録

<p>A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 63 (9), 1261-1267, 2024-05-01

    一般社団法人 日本内科学会

参考文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ